Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks.
about
A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipientsTherapeutic Drug Monitoring, Electronic Health Records, and Pharmacokinetic Modeling to Evaluate Sirolimus Drug Exposure-Response Relationships in Renal Transplant PatientsRegulation of blood-testis barrier (BTB) dynamics during spermatogenesis via the "Yin" and "Yang" effects of mammalian target of rapamycin complex 1 (mTORC1) and mTORC2.Nutrient sensing, autophagy, and diabetic nephropathy.Cardiorenal benefits of early versus late cyclosporine to sirolimus conversion in a rat model.Conversion to sirolimus for chronic renal allograft dysfunction: risk factors for graft loss and severe side effectsClinical application of mTORi based immunosuppression for renal transplantation in India.Treatment of severe lupus nephritis: the new horizon.mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes.Safety and immunologic benefits of conversion to sirolimus in kidney transplant recipients with long-term exposure to calcineurin inhibitors.mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice.Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients.Chronic allograft nephropathy--clinical guidance for early detection and early intervention strategies.Proliferation signal inhibitors in the treatment of lupus nephritis: preliminary experience.The effect of mammalian target of rapamycin inhibition on T helper type 17 and regulatory T cell differentiation in vitro and in vivo in kidney transplant recipients.Rapamycin promotes podocyte autophagy and ameliorates renal injury in diabetic mice.A review on therapeutic drug monitoring of the mTOR class of immunosuppressants: everolimus and sirolimus
P2860
Q27000107-03360286-FE1C-43A6-BF2C-0DD55283DC59Q33432698-FC530FFC-C8A0-4F44-92BC-B9034FD21FADQ33863571-330432F3-E1C7-4C11-A01F-AFBB90270ACBQ35612372-20C29E44-96ED-4691-A554-22637F549D86Q35975228-77F808B8-BCB0-4342-84B5-52A2DCA1BA3DQ36938848-CBB265B0-2DB8-41BD-889D-5E49BFDE7469Q37929851-BF55A439-E62D-4A33-B09C-647D5958E0F7Q38271125-C4921356-37C1-4CF2-B4C4-5367FA26B399Q39914641-219121DC-F95C-4E71-ACE8-F0C88A196742Q40940603-216171E2-B32A-4F03-889B-8D88657F0CB2Q41912848-99D919E6-FF32-4252-B803-5AD1D1A5FDA5Q44779498-48987716-32E5-41B8-A0C1-B08CCF729611Q46667111-5B82D106-3AEF-4813-9F10-A51E13329AC7Q47361768-5C114727-1C93-40D4-99AA-0837F4CD1107Q50796005-41C8E121-910D-447A-888C-336C766BB325Q53048992-18999A55-7D7F-4B28-A0EE-99A547AFE601Q56035477-E944EDFF-4E7C-40A5-92F8-4B4C998CBB7C
P2860
Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Conversion from calcineurin in ...... phropathy: benefits and risks.
@en
Conversion from calcineurin in ...... phropathy: benefits and risks.
@nl
type
label
Conversion from calcineurin in ...... phropathy: benefits and risks.
@en
Conversion from calcineurin in ...... phropathy: benefits and risks.
@nl
prefLabel
Conversion from calcineurin in ...... phropathy: benefits and risks.
@en
Conversion from calcineurin in ...... phropathy: benefits and risks.
@nl
P2860
P356
P1476
Conversion from calcineurin in ...... phropathy: benefits and risks.
@en
P2093
Josep M Campistol
P2860
P304
P356
10.1093/NDT/GFI336
P407
P577
2005-12-16T00:00:00Z